GlobeImmune, Inc. (GBIM)

Market Cap	575.00 -100.0%
Revenue (ttm)	6.21M +8.3%
Net Income	-2.07M
EPS	-0.36
Shares Out	5.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,200
Average Volume	4,073
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0005
Beta	-329.26
RSI	43.37
Earnings Date	n/a

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: GBIM

Financial Performance

In 2015, GlobeImmune's revenue was $6.46 million, an increase of 8.24% compared to the previous year's $5.97 million. Losses were -$2.77 million, -88.19% less than in 2014.